IMUX Immunic, Inc.
Listings ·
Nasdaq approved Immunic's move from the Global Select Market to the Capital Market, with trading there from January 7, 2026. The company now has until June 22, 2026 to regain compliance with the $1.00 minimum bid price and has told Nasdaq it would seek a reverse stock split if necessary.
The company has until December 24, 2025 to regain compliance. The notice has no immediate effect on its listing on The Nasdaq Global Select Market.
Immunic began an underwritten warrant offering on May 28, 2025 and set final terms on May 30: $0.7499 a unit, $64,991,334 in total. Leerink Partners is sole bookrunner.
Immunic agreed on April 9, 2025 to sell 5,666,667 shares at $0.90 each for about $5.1 million, with Titan Partners Group LLC as sole placement agent. The company's 2024 annual report carried a going concern doubt and reported $35.7 million in cash at year end.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $82.0 million | $80.0 million |
| Net income (loss) | -$97.2 million | -$100.5 million |
| Cash from operations | -$85.8 million | -$84.8 million |
| Cash and equivalents | $15.5 million | $35.7 million |
Our latest story on this, dated Jan 6, 2026: "Immunic gets extra 180 days on Nasdaq bid price rule after transfer to Capital Market". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 9, 2025: "Immunic, Inc. prices $5.1 million registered direct offering at $0.90 per share". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 28, 2025: "Immunic launches pre-funded warrant offering; final terms total $64,991,334". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 27, 2025: "Immunic gets Nasdaq notice after stock falls below $1.00 for 30 days". The story links the filing or release it is based on. Read the story.
Immunic, Inc. trades under the ticker IMUX on NASDAQ.
Immunic, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:10V; LS:A428WY; LSX:A428WY.
The SEC Central Index Key (CIK) for Immunic, Inc. is 1280776. Its filings are on SEC EDGAR.
13,644,467 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Immunic, Inc. under United States.
Our directory classifies Immunic, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Immunic, Inc. is US4525EP2001.
aibio.space lists Immunic, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Immunic, Inc. reported a net loss of $97.2 million for the fiscal year ended Dec 31, 2025, and used $85.8 million of cash in operations, per its annual report to the SEC.
$82.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio